AIMS: Both epithelial barrier dysfunction and apoptosis resistance of immune cells contribute to the pathogenesis of Crohn's disease. The soluble decoy receptor 3 (DcR3) acts in an anti-apoptotic manner by neutralising the death ligand CD95L. Here, we investigated the possible involvement of DcR3 in Crohn's disease. METHODS: The epithelial fraction of human small intestinal mucosa samples was obtained by laser microdissection. Expression of DcR3 was examined by global gene expression profiling, quantitative reverse transcription polymerase chain reaction, immunoblot analysis, and immunohistochemistry. DcR3 concentrations in the serum of patients with Crohn's disease were measured by enzyme-linked immunosorbent assay. Apoptosis assays were performed to study the effects of DcR3 in intestinal epithelial cells and lamina propria T cells. RESULTS: DcR3 is over-expressed in the epithelial layer of ileum specimens in patients with Crohn's disease, both at actively inflamed and non-active sites. DcR3 serum levels are significantly elevated in patients with active and non-active Crohn's disease as compared to healthy controls. The expression of DcR3 in intestinal epithelial cells is induced by tumour necrosis factor alpha. Increased DcR3 expression is associated with activation of nuclear factor kappa B (NF-kappaB) and results in protection of intestinal epithelial cells and lamina propria T cells from CD95L-induced apoptosis. CONCLUSIONS: DcR3 may promote inflammation in Crohn's disease by inhibiting CD95L-induced apoptosis of epithelial and immune cells as well as by inducing NF-kappaB activation. 
Results: DcR3 is over-expressed in the epithelial layer of ileum specimens in patients with Crohn's disease, both at actively inflamed and non-active sites. DcR3 serum levels are significantly elevated in patients with active and nonactive Crohn's disease as compared to healthy controls. The expression of DcR3 in intestinal epithelial cells is induced by tumour necrosis factor a. Increased DcR3 expression is associated with activation of nuclear factor kappa B (NF-kB) and results in protection of intestinal epithelial cells and lamina propria T cells from CD95L-induced apoptosis. Conclusions: DcR3 may promote inflammation in Crohn's disease by inhibiting CD95L-induced apoptosis of epithelial and immune cells as well as by inducing NF-kB activation.
The mucosal inflammation in chronic inflammatory bowel disease (IBD) is promoted by epithelial barrier defects, inappropriate innate immune responses, and dysregulations in the adaptive immune system. Resistance of T cells against the induction of apoptotic cell death has been identified as one factor which promotes local T cell accumulation and further perpetuates the chronic mucosal inflammation. 1 Physiologically, T lymphocytes are at least partially eliminated via death receptor-dependent mechanisms in response to stimulation by environmental antigens. Apoptotic death of T cells is accomplished upon binding of the death ligand CD95L to its receptor CD95 or, alternatively, upon binding of the death ligand TRAIL to one of its proapoptotic receptors, TRAIL-R1 or TRAIL-R2. The socalled decoy receptors are proteins that belong to the tumour necrosis factor receptor superfamily and inhibit death ligand-induced apoptosis by binding to and neutralising the death ligands TRAIL and CD95L. Whereas decoy receptors 1 and 2 (DcR1, DcR2) bind to TRAIL, the soluble decoy receptor 3 (DcR3, also known as TR6, M68) interacts with CD95L, LIGHT and TNF-like molecule 1A (TL1A). [2] [3] [4] [5] Some experimental data indicate that over-expression of DcR1, DcR2 and DcR3 might contribute to a diminished induction of apoptosis in T cells from inflamed mucosa in ulcerative colitis. 6 An altered expression and function of cell-cell adhesion proteins such as the intercellular cell adhesion molecule-1 (ICAM-1) might contribute to the development of an epithelial barrier dysfunction in IBD. These proteins are involved in leukocyte trafficking to endothelial and epithelial sites, but can also facilitate pathogen invasion, possibly caused by an increased adherence of bacteria to the luminal surface of the intestinal epithelium. 7 The role of defects in the regulation of apoptosis in enterocytes for the epithelial barrier dysfunction in IBD is less clear. However, apoptosis resistance of enterocytes is considered to be of relevance for the process of IBD-associated carcinogenesis, where a deregulated activation of nuclear factor kappa B (NF-kB)-dependent prosurvival signalling pathways may contribute to the malignant transformation of enterocytes.
To further dissect molecular changes within the epithelial compartment of the gut mucosa in Crohn's disease, we performed a global gene expression analysis of microdissected epithelial fractions of human intestinal tissue. We identified DcR3 as a gene that is over-expressed in the intestinal epithelium in Crohn's disease and we functionally characterised the role of DcR3 in epithelial intestinal cells. Our findings suggest that upregulation of DcR3 is involved in apoptosis resistance, promotion of inflammation in Crohn's disease, and possibly also carcinogenesis.
PATIENTS AND METHODS Patients (tissue and sera)
Resection specimens were obtained from the Department of Surgery, University Hospital Heidelberg. Informed consent was obtained from the patients. Diagnosis was established according to clinical and conventional histopathological criteria. Clinical features of the patients are provided in tables 1 and 2, and in the supplement (parts 1 and 2). For a detailed description of how the inflammatory status (active vs noninflamed/inactive) of the Crohn's disease samples was determined by histopathology, see the supplement (part 3).
Laser microdissection and pressure catapulting
Fresh frozen small intestinal mucosa samples were cut into 18 mm thick sections using a cryostat (Leica CM1850; Leica Microsystems, Wetzlar, Germany) and processed as described in the supplement (part 4).
Isolation of RNA in microdissected samples
Total RNA was isolated from each sample using the Chomczynski/ Sacchi method 8 according to the manufacturer's instructions (peqGOLD TriFast kit; PeqLab Biotechnologie, Erlangen Germany). For precipitation 2 ml of Pellet Paint Co-Precipitant (Novagen, San Diego, California, USA) per sample were used. Subsequently, isolated RNA was purified using an Absolutely RNA Nanoprep Kit (Stratagene, La Jolla, California, USA). The quality of the RNA was assessed on RNA 6000 Nano microfluidics chips (Agilent Technologies, Waldbronn, Germany) on an Agilent 2100 BioAnalyzer according to the manufacturer's instructions.
High-density oligonucleotide microarray analysis
All experiments were performed using Affymetrix HG-U133 Plus 2.0 GeneChips oligonucleotide arrays (Affymetrix, High Wycombe, UK), as described at http://www.affymetrix.com/ products/arrays/specific/hgu133plus.affx (accessed 16 December 2008). Hybridisation, data collection, and data processing were performed as outlined in the supplement (part 5).
Quantitative real-time polymerase chain reaction RNA samples (100 ng total RNA) were reverse-transcribed into cDNA by REVERSE-IT max 1 st strand synthesis kit according to the manufacturer's protocol (Abgene, Hamburg, Germany). Real-time monitoring of PCR reactions was performed as described in the supplement (part 6). 
Inflammatory bowel disease Immunohistochemistry
Tissue sections of non-inflamed (n = 7) and inflamed (active Crohn's disease, n = 6; non-active Crohn's disease, n = 4) small intestine were analysed for DcR3 and ICAM-1 expression by immunohistochemistry. The immunohistochemical staining procedure is outlined in the supplement (part 7).
Enzyme-linked immunosorbent assay of decoy receptor 3
Serum DcR3 levels were measured by the human DcR3-specific quantitative ELISA as described previously. 9 For a brief outline of the procedure, see the supplement (part 8).
Cell lines
SW480 and HCT116 adherent intestinal epithelial cell lines derived from colon adenocarcinomas were maintained in RPMI 1640 (Invitrogen, Karlsruhe, Germany) containing 10% fetal calf serum (FCS), and 1% penicillin-streptomycin (Invitrogen) at 37uC and 5% CO 2 .
Transfections
Stable ectopic expression of DcR3 in SW480 cells was obtained by co-transfecting the cells with the pRK5-DcR3 plasmid 2 and the pcDNA3 neo control plasmid by the lipofectamine method (Lipofectamin 2000; Invitrogen). The cells were selected with G418 (750 mg/ml), starting 48 h after transfection. As controls, stable transfectants were generated with the empty pcDNA3 expression vector. Expression of the transgene was confirmed by immunoblot analysis and PCR.
Immunoblot analysis
Immunoblot analysis was performed as outlined in the supplement (part 9).
Cytotoxicity
HCT116 cells were plated into 96-well plates (20 000 cells/well) and after 24 h treated with leucine zipper-tagged CD95 ligand (LZ-CD95L)-containing supernatants (kindly provided by PH Krammer, Heidelberg), TRAIL (Biomol), human recombinant DcR3 (rhDcR3/Fc chimera, R&D Systems, Wiesbaden, Germany), and/or DcR3-containing supernatants derived from SW480 cells stably transfected with a plasmid encoding human DcR3 cDNA.
2 After 24 h cell survival was measured by crystal violet staining as described previously. 10 
Preparation of T cells from intestinal lamina propria and killing assays
Normal mucosa was dissected from freshly resected gut from patients undergoing partial colectomy for non-IBD-related localised colon cancer. The preparation of lamina propria T cells and the killing assays are described in the supplement (part 10).
Statistical analysis
Data was analysed as outlined in the supplement (part 11). [11] [12] [13] [14] [15] However, the use of total mucosal tissue for such studies does not allow the expression of certain genes to be allocated to a defined tissue compartment within the bowel wall, such as epithelium or lamina propria. To identify genes that are specifically regulated in the epithelial layer of the small intestine in patients with Crohn's disease, we performed MicroImaging-based laser microdissection of freshly obtained small-intestinal tissue samples from actively inflamed as well as non-active areas of specimens with Crohn's disease or non-inflammatory bowel diseases (normal controls). The clinical features of the patients are summarised in table 1 and in the supplement (part 1). One of the genes that was most prominently upregulated in Crohn's disease as compared to controls was the soluble CD95L-neutralising DcR3 ( fig 1A) . Interleukin 8, a cytokine that is classically induced by inflammatory conditions, was upregulated to a similar extent as DcR3 in samples with active Crohn's disease, but not in nonactive Crohn's disease. Interestingly, the pro-apoptotic death ligand CD95L was moderately downregulated in Crohn's disease, as was the NF-kB-regulating gene IkBa. A strong downregulation was also observed for TNF-like molecule 1A (TL1A) which is an alternative binding partner of DcR3.
To confirm the findings of the Affymetrix gene chip analysis in an independent and larger cohort of samples (table 1) , we analysed the expression of DcR3 mRNA in microdissected ileal epithelium by quantitative RT-PCR analysis. DcR3 expression was approximatly 22-fold upregulated in active Crohn's disease as compared to controls ( fig 1B) . The expression of DcR3 in non-active Crohn's disease was moderately, but still significantly, increased when compared to normal control tissues. Moreover, TL1A downregulation was confirmed by quantitative RT-PCR analysis (see the supplement, part 12).
Since mRNA expression levels do not necessarily correspond to protein expression levels, we performed immunoblot analyses using lysates from mucosal tissue specimens of Crohn's disease and controls. In accordance with our finding of elevated DcR3 mRNA levels, the protein expression of DcR3 was strongly upregulated in samples with active Crohn's disease and moderately upregulated in samples with non-active Crohn's disease ( fig 1C) . DcR3 protein expression in normal control ileal mucosa was very weak or absent.
Over-expression of decoy receptor 3 occurs in ulcerative epithelial lesions and in the follicle-associated epithelium
To characterise the localisation of upregulated DcR3 in more detail, we performed immunohistochemical analysis of DcR3 expression in Crohn's disease tissues and controls. The patients and clinical features are summarised in table 2 and the supplement (part 1). Ileal mucosa of normal controls displayed only weak immunoreactivity for DcR3 which was confined to a few scattered lamina propria mononuclear cells and some surface epithelial cells at sites of mucosal lymphoid follicles (fig 2A,B) . Such structures represent a possible site of initial inflammation in IBD. 16 Enhanced immunostaining of such follicle-associated epithelial (FAE) cells for DcR3 was apparent in Crohn's disease tissues, both in samples with non- active  (fig 2C,D) and active (fig 2E,F) disease. In actively inflamed samples, epithelial expression of DcR3 in Crohn's disease was more widespread and included mucosal areas apart from lymphoid follicles, especially in the vicinity of erosions and ulcers (fig 2G-J Increased serum levels of decoy receptor 3 in patients with Crohn's disease Since DcR3 is a soluble protein, we next investigated whether patients suffering from Crohn's disease exhibit increased blood serum concentrations of DcR3 protein. Serum samples from 56 patients with active or non-active Crohn's disease and from 27 healthy control individuals were subjected to ELISA (for clinical details, see the supplement, parts 1 and 2). Irrespective of the presence of active or non-active disease, the DcR3 serum concentrations of patients with Crohn's disease were significantly higher than in the control group (fig 3) . DcR3 levels were not significantly different between active and non-active Crohn's disease.
Tumour necrosis factor a upregulates the expression of decoy receptor 3
Tumour necrosis factor a (TNFa) and interleukins (ILs) are associated with early mucosal changes in IBD, such as epithelial barrier dysfunction and increased local influx of leukocytes. 
Decoy receptor 3 protects epithelial cells from CD95L-induced cell death
To investigate the effects of increased DcR3 expression in intestinal epithelial cells, we generated sublines of SW480 cells that were stably transfected with a DcR3 expression plasmid. In contrast to wild-type or control-transfected SW480 cells, the DcR3-transfected cells produced high amounts of soluble DcR3 ( fig 5A) . The epithelial cell line HCT116 expresses the CD95 death receptor and is susceptible to CD95L-mediated cell death ( fig 5B and the supplement, part 13) . However, when the cells were co-treated with DcR3-containing supernatant from DcR3-transfected cells, the CD95L-induced apoptosis was effectively inhibited. In contrast, cell death induced by TRAIL, another death ligand, was not inhibited by DcR3. To confirm the protective effect of DcR3, we performed similar experiments with human recombinant DcR3 (rhDcR3). CD95L-induced cytotoxicity was completely abrogated by rhDcR3 protein even at low concentrations ( fig 5C) . Again, the extent of TRAILinduced cell death was not altered by recombinant DcR3.
Decoy receptor 3 induces activation of nuclear factor kappa B
TNFa-induced activation of NF-kB-dependent pathways plays an important role in inflammatory bowel disease. 20 Since DcR3 expression can be induced by TNFa, we investigated whether DcR3 itself promotes NF-kB activation. In fact, short-term treatment of intestinal epithelial cells with DcR3 resulted in a substantial degradation of IkBa which indicated NF-kB activation ( fig 6) . Since NF-kB signalling is also involved in the transcriptional control of inflammation-associated adhesion molecules such as ICAM-1, 21 we examined a possible regulatory role of DcR3 in ICAM-1 expression. We investigated the tissue distribution of ICAM-1 in inflamed small bowel specimens in Crohn's disease. ICAM-1 was detected in the endothelium of small blood vessels, in mononuclear cells, and at the luminal surface of enterocytes (fig 7) . The increased expression of ICAM-1 and DcR3 coincided at sites of acute inflammation.
CD95L-induced apoptosis of lamina propria T cells is blocked by decoy receptor 3
Finally, we investigated the effects of increased DcR3 protein levels on the site-specific immune effector cells in human intestinal tissue. Lamina propria T cells were isolated from freshly resected human bowel specimens. After CD3 stimulation the T cells were incubated with CD95L in the presence or absence of DcR3. The CD95L-dependent killing of T cells was significantly more effective in CD3-stimulated T cells than in the non-stimulated controls. However, in the presence of DcR3 the CD95L-mediated killing of T cells was almost completely abolished (see the supplement, part 10).
DISCUSSION
In this study we first tried to identify genes that are differentially regulated in the epithelial compartment of intestinal tissues from patients suffering from Crohn's disease. After microdissecting fresh frozen small-intestinal mucosa samples, the epithelial fraction was subjected to a global expression analysis. These experiments resulted in the identification of DcR3 as one of the genes which is significantly overexpressed in the epithelial compartment in Crohn's disease as compared to non-inflamed normal controls.
The soluble DcR3 protein is a multi-functional modulator of immune responses. The effects of DcR3 on the immune system include inhibition of T cell chemotaxis, blockage of T cell response to alloantigens, regulation of T cell interaction with other immune competent cells, but also co-stimulation of proliferation, lymphokine production, and cytotoxicity of human T cells in the presence of T cell receptor (TCR) ligation. [22] [23] [24] [25] Most of these effects are mediated by the interaction of DcR3 with CD95L, LIGHT or TL1A, but functions of DcR3 which are independent of ligand binding have also been reported, such as increased monocyte adhesion. 26 One study reported elevated expression levels of the decoy receptors DcR1, DcR2 and DcR3 in lamina propria T cells in chronic IBD. 6 With respect to the epithelial compartment, an increased expression of DcR3 has been demonstrated in appendix epithelia from patients with acute appendicitis. 27 However, the functional role of DcR3 in the epithelial compartment in Crohn's disease has not yet been addressed.
Our finding of upregulated epithelial DcR3 expression in Crohn's disease was confirmed by quantitative RT-PCR analysis, immunoblot analysis of mucosal tissues and by immunohistochemistry. Interestingly, the upregulation of DcR3 in the intestinal epithelium in Crohn's disease was paralleled by a downregulation of two of the DcR3 ligands, TL1A and CD95L ( fig 1A and the supplement, part 12 kinase (JNK)-, and NF-kB-dependent signalling pathways. 27 28 Given the importance of LPS and innate bacterial-host interactions for the immune status in the bowel mucosa, these findings in accordance with our results suggest that DcR3 is functionally involved in the pathogenesis of Crohn's disease.
There are several possible consequences of elevated DcR3 production by enterocytes in Crohn's disease. DcR3 may protect enterocytes from CD95L-induced apoptotic cell death which is possibly triggered by cytotoxic T cells at sites of acute inflammation. Moreover, we present evidence that DcR3 induces the activation of NF-kB in intestinal epithelial cells which may lead to the increased transcription of diverse prosurvival genes. Thus, increased DcR3 production by enterocytes could represent a protection mechanism of cells confronted with a microenvironment of chronic inflammation. For endothelial cells, it has been shown that DcR3 induces IkB degradation and NF-kB DNA-binding activity. 29 Moreover, we now demonstrate that DcR3 expression in intestinal epithelial cells is induced by TNFa (fig 4) . In this context, it is of interest that DcR3 was reported to be induced by TNFa in rheumatoid synovial fibroblasts. 30 Given the induction of DcR3 by TNFa and the DcR3-mediated activation of NF-kB, DcR3 appears to be functionally involved in the TNFa-dependent NF-kB regulation in enterocytes. Since our respective experiments are cell culture-based, future in vivo investigations are needed to dissect the molecular mechanisms and possible redundancies in the mutual relationship between DcR3, TNFa and NF-kB. The activation of NF-kB-dependent pro-survival and proliferation pathways plays an important role in many models of tumorigenesis. Besides its immunoregulatory functions, DcR3 is known to be over-expressed in many types of cancer, eg, lung and gastrointestinal tract tumours and malignant gliomas. 2 31-33 Since NF-kB activation has been implicated as an important factor in the pathogenesis of colitis-associated colon carcinomas, 34 DcR3 could very well play a role in the development of IBD-associated colon cancer.
In light of the epithelial barrier dysfunction in IBD it is intriguing that DcR3-dependent NF-kB activation has been shown to upregulate cell-cell adhesion proteins such as ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1), thereby increasing the adhesion of monocytes to endothelial cells. 29 The DcR3-induced increase in monocyte adhesion may be mediated by the formation of cross-links between DcR3 and proteoglycans. 26 Immobilised DcR3 was also shown to induce actin reorganisation, thereby enhancing the adhesion of monocytes. 35 We demonstrate that DcR3 and ICAM-1 are coexpressed in the chronically inflamed mucosa at sites of acute Figure 4 Transcriptional regulation of decoy receptor 3 (DcR3) expression by tumour necrosis factor a (TNFa). HCT116 cells were incubated with TNFa (10 ng/ml) or interleukin 1b (IL1b; 10 ng/ml) for 12 h or 24 h. Subsequently, RNA was extracted and subjected to quantitative real-time polymerase chain reaction (RT-PCR) analysis of DcR3 (A) or IL8 (B). Data are presented as mean with the standard deviation (SD) (n = 3, t test, *p,0.05, **p,0.001, ***p,0.0001, compared to controls; representative data from one of several independent experiments with similar results are shown). inflammation. Recent evidence suggests that ICAMs are involved in leukocyte trafficking at endothelial or epithelial surfaces and also play a role as target structures for viral and bacterial pathogens at the intestinal mucosa. 7 ICAM-1 is known to be expressed at the follicle-associated epithelium (FAE), suggesting a role in antigen sampling at such sites. Interestingly, DcR3 showed a very similar expression pattern with the presence of DcR3-positive cells in the FAE (fig 2) . These findings suggest that DcR3-mediated regulation of ICAM-1 might play a functional role in the invasion of pathogens and in the epithelial/endothelial trafficking of leukocytes in Crohn's disease.
Besides its strong expression at sites of acute inflammation, DcR3 is predominantly expressed at the FAE in the mucosa of patients with Crohn's disease. This finding could explain why elevated DcR3 serum levels were observed not only in patients with active Crohn's disease, but also in patients with non-active Crohn's disease (fig 3) . Future detailed studies are required to address the question whether DcR3 serum levels or mucosal biopsies could be used as a biological marker for early manifestations of Crohn's disease.
Finally, we present evidence that upregulated DcR3 expression in epithelial intestinal cells could also result in the blockage of CD95L-dependent killing of lamina propria T cells (see the supplement, part 10). Thus, locally elevated DcR3 tissue concentrations could lead to the inhibition of CD95-mediated activation-induced cell death of T cells, thereby contributing to the accumulation of T lymphocytes in the chronically inflamed mucosa.
Taken together, our results suggest that the soluble DcR3 protein is functionally relevant in the development and progression of Crohn's disease. Elevated DcR3 expression is not specific for Crohn's disease, since DcR3 is also involved in other inflammatory and neoplastic conditions. This might limit the possible use of DcR3 serum levels as a marker for Crohn's disease. However, our finding of increased DcR3 expression even in non-inflamed gut areas in Crohn's disease is important and suggests that DcR3 is involved early in the disease process. Increased ICAM-1 expression and the DcR3-dependent protection of lamina propria T cells from CD95L-induced cell death might contribute to the perpetuation of inflammatory changes in Crohn's disease. The DcR3-mediated activation of NF-kB prosurvival signalling pathways and the protection from CD95-induced cell death may play a role in the transformation of enterocytes to dysplastic cells and, finally, carcinoma cells. Thus, DcR3 might represent an important molecular link between inflammation and carcinogenesis in IBD. Future investigations using rodent models with transgenic DcR3 expression 36 will further characterise the functional relevance of DcR3 in chronic intestinal inflammation.
